Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Lakshini Yasaswi HeratJennifer MatthewsOmar AzzamMarkus P SchlaichVance B MatthewsPublished in: Current hypertension reports (2022)
SGLT2 inhibitors have shown enormous potential to improve cardiovascular outcomes in patients with type 2 diabetes, and their therapeutic potential is currently being investigated in a range of associated comorbidities such as heart failure and chronic kidney disease. Indeed, recent experimental data in relevant animal models highlight a bidirectional interaction between sympathetic nervous system activation and SGLT2 expression, and this facilitates several of the features associated with SGLT2 inhibition observed in clinical trials including improved glucose metabolism, weight loss, increased diuresis, and lowering of blood pressure. Currently available data highlight the various levels of interaction between the sympathetic nervous system and SGLT2 expression and explores the potential for SGLT2 inhibition as a therapeutic strategy in conditions commonly characterised by sympathetic activation.
Keyphrases
- metabolic syndrome
- chronic kidney disease
- heart failure
- blood pressure
- clinical trial
- poor prognosis
- weight loss
- electronic health record
- big data
- bariatric surgery
- end stage renal disease
- binding protein
- randomized controlled trial
- type diabetes
- adipose tissue
- atrial fibrillation
- data analysis
- climate change
- risk assessment
- cancer therapy
- human health
- machine learning
- artificial intelligence
- study protocol
- blood glucose
- gastric bypass
- cardiovascular risk factors